Prolactin exerts hematopoietic growth-promoting effects in vivo and partially counteracts myelosuppression by azidothymidine

Experimental Hematology

Volumn 27, Issue 5, 1999, Pages 811-816

  Woody, Mary Alice ^a   Welniak, Lisbeth A ^a   Sun, Rui ^b   Tian, Zhi Gang ^a   Henry, Michelle ^a   Richards, Susan ^d   Raziuddin, Arati ^b   Longo, Dan L ^c   Murphy, William J ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d GENZYME CORPORATION   (United States)

Author keywords

Hematopoiesis; Myeloid progenitors; Neuroendocrine hormone; Prolactin

Indexed keywords

ERYTHROPOIETIN; PROLACTIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT HORMONE; RECOMBINANT INTERLEUKIN 3; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BURST FORMING UNIT E; COLONY FORMING UNIT GM; COLONY FORMING UNIT S; CONTROLLED STUDY; DRUG EFFECT; ERYTHROID PRECURSOR CELL; HEMATOCRIT; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROMYELOCYTE;

ANIMALS; ANTI-HIV AGENTS; CELL DIVISION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; PROLACTIN; RECOMBINANT PROTEINS; ZIDOVUDINE;

ANIMALIA;

EID: 0032920967     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(99)00019-3     Document Type: Article

References (42)

1. Bazan J. Haemopoietic receptors and helical cytokines. Immunol Today. 11:1990;350.
2. Kelly P., Ali S., Rozakis M., Goujon L., Nagano M., Pellegrini I., Gould D., Djiane J., Edery M., Finidori J. The growth hormone/prolactin receptor family. Recent Progr Horm Res. 48:1993;123.
3. Rui H., Kirken R., Farrar W.L. Activation of receptor-associated tyrosine kinase JAK2 by prolactin. J Biol Chem. 269:1994;5364.
4. Murphy W., Rui H., Longo D. Effects of growth hormone and prolactin immune development and function. Life Sci. 57:1995;1.
5. Pellegrini I., Lebrun J., Ali S., Kelly P. Expression of prolactin and its receptor in human lymphoid cells. Mol Endocrinol. 6:1992;1023.
6. Bellone G., Geuna M., Carbone A., Silvestri S., Foa R., Emaneulli G., Matera L. Regulatory action of prolactin on the in vitro growth of CD34+ve human hemopoietic progenitor cells. J Cell Physiol. 163:1995;221.
7. Bellone G., Astarita P., Artusio E., Silvestri S., Mareschi K., Turletti A., Buttiglieri S., Emanuelli G., Matera L. Bone marrow stroma-derived prolactin is involved in basal and platelet-activating factor-stimulated in vitro erythropoiesis. Blood. 90:1997;21.
8. Gala R. Prolactin and growth hormone in the regulation of the immune system. Proc Soc Exp Biol Med. 198:1991;513.
9. Kooijman R., Malur A., Van Buul-Offers S., Hooghe-Peters E. Growth hormone expression in murine bone marrow cells is independent of the pituitary transcription factor pit-1. Endocrinology. 138:1997;3949.
10. Berczi I., Nagy E. Placental lactogen is a haemopoietic hormone. Br J Haematol. 79:1991;355.
11. Nagy E., Berczi I. Hypophysectomized rats depend on residual prolactin for survival. Endocrinology. 128:1991;2776.
12. Murphy W., Durum S., Anver M., Longo D. Immunologic and hematologic effects of neuroendocrine hormones. Studies on DW/J dwarf mice. J Immunol. 148:1992;3799.
13. Nagy E., Berczi I. Pituitary dependence of bone marrow function. Br J Haematol. 71:1989;457.
14. Gala R. The influence of thyroxine, growth hormone and prolactin alone and in combination on the production of prolactin-like activity by splenocytes from Snell dwarf mice. Life Sci. 57:1995;113.
15. Nagy E., Berczi I., Friesen H. Regulation of immunity in rats by lactogenic and growth hormones. Acta Endocrinol (Copenh). 102:1983;351.
16. Horseman N., Zhao W., Montecino-Rodriquez E., Tanaka M., Nakashima K., Engle S., Smith F., Markoff E., Dorshkind K. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J. 16:1997;6926.
17. Bradley T., Hodgson G. Detection of primative macrophage progenitor cells in mouse bone marrow. Blood. 54:1979;1446.
18. Murphy W., Tsarfaty G., Longo D. Growth hormone exerts hematopoietic growth-promoting effects in vivo and partially counteracts the myelosuppressive effects of azidothymidine. Blood. 80:1992;1443.
19. Stephenson J., Axelrad A., McLeod D., Shreeve M. Induction of colonies of hemoglobin-synthesizing cells by erythropoietin in vitro. Proc Natl Acad Sci U S A. 68:1971;1542.
20. Murphy W., Durum S., Longo D. Differential effects of growth hormone and prolactin on murine T cell development and function. J Exp Med. 178:1993;231.
21. Berczi I., Nagy E., Kovacs K., Horvath E. Regulation of humoral immunity in rats by pituitary hormones. Acta Endocrinol (Copenh). 98:1981;506.
22. Nagy E., Berczi I. Immunodeficiency in hypophysectomized rats. Acta Endocrinol (Copenh). 89:1978;530.
23. Nagy E., Berczi I., Wren G., Asa S., Kovacs K. Immunomodulation by bromocriptine. Immunopharmacology. 6:1983;231.
24. Matera L., Bellone G., Cesano A. Prolactin and the neuroimmune network. Adv Neuroimmunol. 1:1991;158.
25. Chen Y., Johnson A. In vivo activation of macrophages by prolactin from young and aging mice. Int J Immunopharmacol. 15:1993;39.
26. Bernton E., Meltzer M., Holaday J. Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. Science. 239:1988;401.
27. Zhu X.-H., Zellweger R., Wichmann M., Ayala A., Chaudry I. Effects of prolactin and metoclopramide on macrophage gene expression in late sepsis. Cytokine. 9:1977;437.
28. Richman D.D., Fischl M.A., Grieco M., Gottlieb M., Volberding P., Laskin O., Leedom J., Groopman J., Mildvan D., Hirsch M., Jackson G., Durack D.et al. The AZT collaborative working group. the toxicity of azidothymidine (AZT) in the treatment of patients with AIDA and AIDS-related complex. A double-blind, placebo-controlled trial N Engl J Med. 317:1987;192.
29. Weinthal J. the role of cytokines following bone marrow transplantation. indications and controversies Bone Marrow Transplant. 18:1996;S10.
30. Miles S., Mitsuyasu R., Moreno J., Baldwin G., Alton N., Souza L., Glaspy J. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood. 77:1991;2109.
31. Du X., Neben T., Goldman S., Williams D. Effects of recombinant interleukin-11 on hematopoietic reconstitution in transplant mice. acceleration of recovery of peripheral blood neutrophils and platelets Blood. 81:1993;27.
32. Ishibashi T., Kimura H., Shikama Y., Uchida T., Kariyone S., Hirano T., Kishimoto T., Takatsuki F., Akiyama Y. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 74:1989;1241.
33. Hill R., Warren M., Levin J. Stimulation of thrombopoiesis in mice by human recombinant interleukin-6. J Clin Invest. 85:1990;1242.
34. Smith J., Longo D., Alvord W., Janik E., Sharfman W., Gause B., Curti B., Creekmore S., Holmlund J., Fenton R., Sznol M., Miller L.et al. The effects of treatment with interleukin-1a on platelet recovery after high-dose carboplatin. N Engl J Med. 328:1993;756.
35. Stuart A., Petros W., Crawford E., Rabinowitz J., Peters W. Correlation of endogenous serum IL-6 concentrations with toxicity following high dose chemotherapy with autologous bone marrow support. Blood. 76(suppl):1990;167a.
36. Smith J.N., Urba W., Curti B., Elwood L., Steis R., Janik J., Sharfman W., Miller L., Fenton R., Conlon K., Sznol M., Creekmore S.et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol. 10:1992;1142.
37. Levine J., Allan J., Tessitore J., Falcone N., Galasso F., Israel R., Groopman J. Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex. Blood. 78:1991;3148.
38. Provinciali M., Di Stefano G., Stronati S., Raffaeli W., Pari G., Fabris N. Role of prolactin in the modulation of NK and LAK cell activity after short- or long-term morphine administration in neoplastic patients. Int J Immunopharmacol. 18:1996;577.
39. Matera L., Cesano A., Bellone G., Oberholtzer E. Modulatory activity of prolactin on the resting and mitogen-induced activity of T, B, and NK lymphocytes. Brain Behav Immun. 6:1992;409.
40. Muzzioli M., Mocchegiani E., Bressani N., Bevilacqua P., Fabris N. In vitro restoration by thymulin of NK actvity of cells from old mice. Int J Immunopharmacol. 14:1992;57.
41. Kwa H., Cleton F., Wang D., Bulbrook R.D., Bulstrade J.C., Hayward J.L., Millis R.R., Cuzick J. A prospective study of plasma prolactin levels and subsequent risk of breast cancer. Int J Cancer. 28:1981;673.
42. Ormandy C., Hall R., Manning D., Robertson J., Blamey R., Kelly P., Nicholson R., Sutherland R. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab. 82:1997;3692.